Shots: The US FDA has granted EUA to Nirmidas’ COVID-19 rapid antibody IgG/IgM test for use in POC settings, delivering results in 15-20min Using a fingerstick serology test, the MidaSpot COVID-19 Ab combo detection kit checks for Ab against the RBD antigen and showed 100% sensitivity for IgG after 14 days post symptom onset and […]Read More
Shots: The company reported encouraging initial data from an ongoing P-I/II/III trial of its casirivimab + imdevimab (8,000/2,400mg) in hospitalized COVID-19 patients requiring low-flow oxygen. The results passed the futility analysis as seronegative patients treated with the Ab cocktail had a lower risk of death or receiving mechanical ventilation In seronegative patients, the cocktail reduced […]Read More
Shots: Abbott received CE Mark for its new quantitative SARS-CoV-2 IgG lab-based serology test. The test measures levels of IgG Abs to help in the evaluation of a person’s immune response The study to determines the clinical performance of Abbott’s SARS-CoV-2 IgG II Quant test on its Alinity i instrument showed that it had 99.60% […]Read More
Shots: The company presented the new data of its T-cell engaging bispecific Abs, mosunetuzumab, glofitamab and cevostamab at ASH 2020, demonstrating encouraging activity across multiple types of blood cancer Roche divulges that its mosunetuzumab & glofitamab showed promising responses across multiple types of NHL, including R/R FL & DLBCL, reinforcing from the P-I/Ib GO29781 study […]Read More
Shots: The companies collaborated to evaluate the usability of DNA Link’s AccuFind COVID-19 IgG antibody test in a healthcare setting The study intends to expand access to antibody testing outside of laboratory settings The companies plan to launch the study in Dec’2020 Click here to read full press release/ article | Ref: PRNewswire | Image: Base 10 geneticsRead More
Shots: Abbott has received the US FDA’s EUA for AdviseDx SARS-CoV-2 IgM lab-based serology test for use on the ARCHITECT and Alinity platforms Till now, Abbott has received EUA for its seven tests, including molecular tests, a rapid antigen test and, an IgG Ab test for COVID-19 The IgM test demonstrated 99.56% specificity and 95.00% […]Read More
Shots: The two studies of AZD7442 will enroll ~6,000 adults for the prevention of COVID-19 in and outside the US, expected to begin in next wk. with additional trials enrolling ~4,000 adults for the treatment of SARS-CoV-2 infections. The first study will evaluate the safety and efficacy of AZD7442 to prevent infection for up to […]Read More
Shots: AstraZeneca has licensed Vanderbilt University’s coronavirus-neutralizing Abs & plans to advance a pair of these mAbs into clinical development as a combination therapy for COVID-19. The agreement follows AstraZeneca and Vanderbilt collaboration in Apr’20 AstraZeneca has evaluated the ability of 1,500+ mAbs to bind to the SARS-CoV-2 virus and inhibit its capacity to infect […]Read More
Shots: Eli Lilly reported that first patients have been dosed in a P-I study of LY-CoV555, the first Ab emerge from the collaboration b/w Lilly & AbCellera to create Ab therapies against COVID-19. The P-I J2W-MC-PYAA study aims to evaluate the safety, tolerability, PK/PD of LY-CoV555 following a single dose administered to participants hospitalized for […]Read More
Shots: Sorrento to get access to plasma containing anti-COVID-19 Abs for identifying and produce mAbs with neutralizing activity against SARS-CoV-2. The company expects to commence the P-I study of triple Ab combination therapy in Q3’20 The focus of the collaboration is to jointly develop Ab cocktail which will act as a protective shield against COVID-19 […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
